New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:50 EDTABIOARCA Biopharma prices $9M common stock and warrant offering
ARCA Biopharma announced that it has priced its previously announced public offering of common stock and warrants at a price of $1.70 for each share of common stock and a related warrant to purchase 0.25 shares of common stock, for gross proceeds of $8.7 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company. Dawson James Securities, Inc. is acting as the sole book-running manager for the offering.
News For ABIO From The Last 14 Days
Check below for free stories on ABIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
08:32 EDTABIOARCA Biopharma announces screening of first patient in Phase 2B/3 trial
ARCA biopharma announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro as a potential treatment for the prevention of atrial fibrillation in patients with heart failure and/or left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor, which is believed to be present in approximately 50% of the U.S. population. There are currently seven active clinical trial sites recruiting patients for GENETIC-AF. The company anticipates having approximately 50 clinical trial sites for the Phase 2B portion of the trial. Last week, ARCA hosted the initial GENETIC-AF Investigator Meeting which brought together the physicians and research coordinators participating in the trial for information sharing and study-specific training.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use